Prenetics Global (NASDAQ:PRE) CFO Brian Rosin Buys 18,000 Shares

Prenetics Global Limited (NASDAQ:PRE) CFO Brian Rosin bought 18,000 shares of the firm’s stock in a transaction on Monday, August 24th. The shares were acquired at an average cost of $21.19 per share, with a total value of $381,420.00. Following the purchase, the chief financial officer directly owned 18,000 shares of the company’s stock, valued at approximately $381,420. This represents a ? increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Prenetics Global Stock Up 10.9%

Shares of PRE opened at $25.78 on Thursday. The stock has a market cap of $434.91 million, a P/E ratio of -6.20 and a beta of 0.26. The business’s 50 day moving average price is $19.24 and its 200-day moving average price is $18.98. Prenetics Global Limited has a 52 week low of $7.27 and a 52 week high of $26.29.

Prenetics Global (NASDAQ:PRE) last released its earnings results on Wednesday, August 19th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.31. Prenetics Global had a negative return on equity of 21.41% and a negative net margin of 47.43%.The business had revenue of $46.49 million for the quarter, compared to the consensus estimate of $49.85 million. On average, equities analysts anticipate that Prenetics Global Limited will post -1.86 EPS for the current year.

Analyst Upgrades and Downgrades

PRE has been the topic of a number of research analyst reports. Benchmark increased their price objective on shares of Prenetics Global from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Wall Street Zen upgraded shares of Prenetics Global from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Prenetics Global in a research report on Friday, July 17th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Prenetics Global has an average rating of “Moderate Buy” and a consensus price target of $34.25.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. State of Wyoming bought a new stake in Prenetics Global during the first quarter valued at about $48,000. Wells Fargo & Company MN purchased a new position in Prenetics Global in the 4th quarter worth approximately $47,000. JPMorgan Chase & Co. bought a new position in shares of Prenetics Global during the third quarter worth $65,000. Operose Advisors LLC purchased a new position in Prenetics Global during the 2nd quarter valued at approximately $129,000. Finally, Manatuck Hill Partners LLC bought a new stake in Prenetics Global in the 4th quarter worth approximately $170,000. Institutional investors own 25.01% of the company’s stock.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.